Psilocybin as a Treatment for Chronic Pain in Smokers
Part of paid clinical trials in West Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07118332
- Phase
- EARLY_PHASE1
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Smokers With Chronic Pain
Eligibility Criteria
- Sex
- ALL
- Age
- 21 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Psilocybin (drug) — DRUG25mg of Psilocybin will be given to all subject
Study Details
The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms." Psilocybin is currently being studied in clinical trials but has no current medical use in the United States. Some studies have shown that a dose of psilocybin can help people quit smoking. Other studies have shown that a dose of psilocybin may improve certain chronic pain conditions, such as migraine headaches. We believe that it may also be helpful for people who smoke and have chronic pain, but this has not been tested yet.
Key Dates
- Start date
- Jul 31, 2026
- Status verified
- Jun 2026
- Primary completion
- Oct 1, 2027
- Completion
- Dec 1, 2027
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Psilocybin 25mg
Primary Outcome Measure
SAFTEE scale [ Time Frame: Day 1 and Day 7 ]
Central Contacts
- Mehmet Sofuoglu, M.D., Ph.D.203-932-5711
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Department of Veterans Affairs | West Haven | Connecticut | 06516 | Mehmet Sofuoglu, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) |